These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15485610)

  • 1. Recent reminders of why the gold standard for clinical research in oncology is the well-designed and conducted randomized phase III trial.
    Markman M
    Curr Oncol Rep; 2004 Nov; 6(6):421-2. PubMed ID: 15485610
    [No Abstract]   [Full Text] [Related]  

  • 2. [Phase III trials in oncology].
    Imadalou K; Cvitkovic E
    Bull Cancer; 1999 Feb; 86(2):143-7. PubMed ID: 10066944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New designs for basket clinical trials in oncology.
    Simon R
    J Biopharm Stat; 2018; 28(2):245-255. PubMed ID: 28877003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing.
    Vickers AJ; Ballen V; Scher HI
    Clin Cancer Res; 2007 Feb; 13(3):972-6. PubMed ID: 17277252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innovation in oncology clinical trial design.
    Verweij J; Hendriks HR; Zwierzina H;
    Cancer Treat Rev; 2019 Mar; 74():15-20. PubMed ID: 30665053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sample size determination for the current strategy in oncology Phase 3 trials that tests progression-free survival and overall survival in a two-stage design framework.
    Nomura S; Hirakawa A; Hamada C
    J Biopharm Stat; 2018; 28(4):589-611. PubMed ID: 28886305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness research in oncology: an overview.
    Lyman GH; Levine M
    J Clin Oncol; 2012 Dec; 30(34):4181-4. PubMed ID: 23071249
    [No Abstract]   [Full Text] [Related]  

  • 8. Processes to activate phase III clinical trials in a cooperative oncology group: the elephant is monstrous.
    Steensma DP
    J Clin Oncol; 2007 Mar; 25(9):1148; author reply 1148-9. PubMed ID: 17369584
    [No Abstract]   [Full Text] [Related]  

  • 9. The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology.
    Barton S; Peckitt C; Sclafani F; Cunningham D; Chau I
    Eur J Cancer; 2015 Dec; 51(18):2732-9. PubMed ID: 26608121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is it time to abandon complete blinded independent central radiological evaluation of progression in registration trials?
    Pignatti F; Hemmings R; Jonsson B
    Eur J Cancer; 2011 Aug; 47(12):1759-62. PubMed ID: 21641204
    [No Abstract]   [Full Text] [Related]  

  • 11. A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines.
    Mistry P; Dunn JA; Marshall A
    BMC Med Res Methodol; 2017 Jul; 17(1):108. PubMed ID: 28720094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of randomization-based causal methods with and without integrating external data sources for adjusting overall survival in case of extensive treatment switches in placebo-controlled randomized oncology phase 3 trials.
    Nomura S; Shinozaki T; Hamada C
    J Biopharm Stat; 2020 Mar; 30(2):377-401. PubMed ID: 31820674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B.
    Dilts DM; Sandler AB; Baker M; Cheng SK; George SL; Karas KS; McGuire S; Menon GS; Reusch J; Sawyer D; Scoggins M; Wu A; Zhou K; Schilsky RL;
    J Clin Oncol; 2006 Oct; 24(28):4553-7. PubMed ID: 17008694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?
    Cheng S; McDonald EJ; Cheung MC; Arciero VS; Qureshi M; Jiang D; Ezeife D; Sabharwal M; Chambers A; Han D; Leighl N; Sabarre KA; Chan KKW
    J Clin Oncol; 2017 Aug; 35(24):2764-2771. PubMed ID: 28574778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controversy trails adaptive clinical trials.
    Goozner M
    J Natl Cancer Inst; 2012 Sep; 104(18):1347-8. PubMed ID: 22984199
    [No Abstract]   [Full Text] [Related]  

  • 16. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
    Pond GR; Abbasi S
    Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical research in oncology: problems and prospects for studying biological drugs].
    Tonato M
    Suppl Tumori; 2004; 3(4):S3-4. PubMed ID: 15206197
    [No Abstract]   [Full Text] [Related]  

  • 18. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.
    Stone AM; Bushnell W; Denne J; Sargent DJ; Amit O; Chen C; Bailey-Iacona R; Helterbrand J; Williams G;
    Eur J Cancer; 2011 Aug; 47(12):1763-71. PubMed ID: 21435858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A strategic framework for novel drug development in multiple myeloma.
    Anderson KC; Hannah AL; Pazdur R; Farrell AT
    Br J Haematol; 2007 Jul; 138(2):153-9. PubMed ID: 17593022
    [No Abstract]   [Full Text] [Related]  

  • 20. Translation failure and medical reversal: Two sides to the same coin.
    Prasad V
    Eur J Cancer; 2016 Jan; 52():197-200. PubMed ID: 26689866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.